Brain and Neuroscience Advances

Voltage-gated calcium channels: Their discovery, function and importance as drug targets

Annette C. Dolphin

Abstract
This review will first describe the importance of Ca\(^{2+}\) entry for function of excitable cells, and the subsequent discovery of voltage-activated calcium conductances in these cells. This finding was rapidly followed by the identification of multiple subtypes of calcium conductance in different tissues. These were initially termed low- and high-voltage activated currents, but were then further subdivided into L-, N-, P Q-, R- and T-type calcium currents on the basis of differing pharmacology, voltage-dependent and kinetic properties, and single channel conductance. Purification of skeletal muscle calcium channels allowed the molecular identification of the pore-forming and auxiliary \(\alpha_{2}\beta\delta\gamma\) subunits present in these calcium channel complexes. These advances then led to the cloning of the different subunits, which permitted molecular characterisation, to match the cloned channels with physiological function. Studies with knockout and other mutant mice then allowed further investigation of physiological and pathophysiological roles of calcium channels. In terms of pharmacology, cardiovascular L-type channels are targets for the widely used antihypertensive 1,4-dihydropyridines and other calcium channel blockers, N-type channels are a drug target in pain, and \(\alpha_{2}\beta\delta\gamma - 1\) is the therapeutic target of the gabapentinoid drugs, used in neuropathic pain. Recent structural advances have allowed a deeper understanding of Ca\(^{2+}\) permeation through the channel pore and the structure of both the pore-forming and auxiliary subunits. Voltage-gated calcium channels are subject to multiple pathways of modulation by G-protein and second messenger regulation. Furthermore, their trafficking pathways, subcellular localisation and functional specificity are the subjects of active investigation.

Keywords
Calcium, channel, voltage, second messenger, neuron, heart

Introduction: the importance of Ca\(^{2+}\) entry for function of excitable cells
It has been clear from the time of Sydney Ringer, working at University College London, that calcium ions (Ca\(^{2+}\)) are essential for heart muscle contraction (Ringer, 1883). However, the paramount importance of Na\(^{+}\) and K\(^{+}\) for the activation and inactivation underlying action potential generation led to Ca\(^{2+}\) permeation being little studied for many years. In the 1950’s Paul Fatt, working at University College London with both Katz and Ginsborg, found that Ca\(^{2+}\) supports action potential-like spikes in crustacean muscle (Fatt and Ginsborg, 1958; Fatt and Katz, 1953), and this was also found to be true in barnacle muscle (Hagiwara and Takahashi, 1967). When it was also identified that Ca\(^{2+}\) was essential for neurotransmitter release (Katz and Miledi, 1967), it became clear that calcium ion entry through membranes was key to many important processes in nerves as well as muscle. These key players in the field are pictured in Figure 1(a)–(d).

Identification of multiple subtypes of calcium channel
A major contribution to the understanding of calcium channel function then came from Harald Reuter (Figure 1(e)), who showed, using microelectrodes, that calcium currents were present in voltage-clamped cardiac Purkinje fibres (Reuter, 1967). The advent of the gigaseal patch-clamp method for recording currents through the membrane of single cells (Hamill et al., 1981) then allowed single calcium channels to be resolved (Fenwick et al., 1982).

The discovery and use of verapamil, and the 1,4-dihydropyridines (DHPs) including nifedipine, as antihypertensive drugs represented a very important advance (Fleckenstein, 1983) (Figure 1(f)). Their target was found to be inhibition of cardiovascular calcium channels (Lee and Tsien, 1983); thus, the term calcium channel blocker or antagonist was coined. Related drugs were found to have agonist effects (Schramm et al., 1983), to increase cardiac calcium conductance and prolong single channel openings (Hess et al., 1984). Both the agonist and antagonist...
drugs gave researchers important tools to dissect calcium channel function in a variety of tissues.

The first suggestion that there was more than one component to calcium currents in different tissues came from the group of Hagiwara et al. (1975), followed by evidence of low threshold \( \Ca^{2+} \) spikes in mammalian central neurons (Llinás and Yarom, 1981), and distinct low voltage-activated currents in peripheral dorsal root ganglion neurons (Carbone and Lux, 1984; Fedulova et al., 1985; Nilius et al., 1985).

Identification of N-, P- and R-type calcium currents as distinct from L-type channels

In dorsal root ganglion (DRG) neurons, it was then found that there were three calcium current components. The DHP-sensitive current was designated L-type (for long-lasting, which also had a large single channel conductance) and the low-voltage activated component was termed T (for transient, which also had a tiny single channel conductance). A third component, which was high-voltage activated but DHP-insensitive, was termed N-type (neither L nor T, and also exclusively Neuronal) (Fox et al., 1987; Nowycky et al., 1985) (Figure 2(a)). A blocker of this component was not long in appearing. A toxin component from the marine snail *Conus geographus*, \( \omega \)-conotoxin GVIA, first thought to block both neuronal L- and N-type calcium currents (McCleskey et al., 1987), was later found to be highly selective for N-type channels (Boland et al., 1994; Plummer et al., 1989). Using this pharmacological blocker, N-type calcium currents were then shown to play a key role in neurotransmitter release (Hirning et al., 1988).

The importance of pharmacological tools in the discovery of calcium channel subtypes became even more evident when it was found that the calcium current in Purkinje neurons was not blocked by DHPs or by \( \omega \)-conotoxin GVIA. This current was called P-type (for Purkinje) (Llinás et al., 1989). The same group used a polyamine toxin (FTX) from the American funnel web spider to block Purkinje cell \( \Ca^{2+} \) currents, but FTX was not particularly selective for P-type channels, whereas a peptide toxin component from the same spider (\( \omega \)-agatoxin IV A) was more selective, blocking fully the calcium current in Purkinje neurons (Mintz et al., 1992). This toxin also inhibited a component of the calcium current in cerebellar granule cells (Pearson et al., 1995;
Randall and Tsien, 1995), which was initially termed Q-type as it had different biophysical properties from that in Purkinje neurons (Randall and Tsien, 1993); however, these are usually now called PQ currents. That study also identified an additional resistant current component in cerebellar granule cells which was designated R-type (Randall and Tsien, 1995), and a similar novel component was also identified in bullfrog sympathetic neurons (Elmslie et al., 1994). A tarantula toxin, SNX-482, was identified to block this component (Newcomb et al., 1998), but it has subsequently been found also to block other channels (Kimm and Bean, 2014), complicating interpretation of physiological experiments using SNX-482.

**Purification and molecular identification of the calcium channel subtypes**

Receptors for the DHP calcium antagonists were identified using [3H]-nitrendipine to guide purification. They were found to be highly concentrated in the t-tubules of skeletal muscle (Fosset et al., 1983), where they were shown to be responsible for charge movement and excitation-contraction coupling (Rios and Brum, 1987). Purification studies identified the skeletal muscle DHP receptor to be a complex of five polypeptides in approximately equal amounts, and therefore considered to be subunits. They were termed, in decreasing order of size, the α1, α2, β, γ and δ subunits (Hosey et al., 1987; Takahashi et al., 1987). The 175 kDa α1 subunit was tentatively identified as the pore-forming subunit of the channel, since it bound radiolabelled DHP. The associated proteins were termed auxiliary or accessory subunits.

Peptide sequence from the purified DHP receptor protein enabled the identification of probes and subsequent cloning of the skeletal muscle calcium channel (Ellis et al., 1988; Tanabe et al., 1989). Prior to these studies (Berrow et al., 1995; Qin et al., 1998). The importance of these subunits to the calcium channel was clear from anti-sense knockdown studies in native tissues and early expression studies (Berrow et al., 1995; Qin et al., 1998). In contrast, the CaV3 channels do not appear to have any obligate auxiliary subunits.

When the auxiliary α,δ subunit was cloned, it was realised that α, and δ are encoded by the same gene and form a pre-protein, which is then proteolytically cleaved, but the α and δ proteins remain associated by pre-formed disulfide bonding (De Jongh et al., 1990; Jay et al., 1991). Its proteolytic cleavage has recently been shown to be essential for the α,δ function (Kadurin et al., 2016). The skeletal muscle α,δ subunit was subsequently termed α,δ-1, when three further mammalian isoforms were identified: α,δ-2 (Barclay et al., 2001; Gao et al., 2000), α,δ-3 and α,δ-4 (Qin et al., 2002). The muscle α,δ subunit was first described as a transmembrane protein, but they have subsequently been shown to be glycospatidilinositol (GPI)-anchored into the outer leaflet of the plasma membrane (Davies et al., 2010) (Figure 2(b)). The α,δ subunit was predicted to contain a von Willebrand factor A (VWA) domain, which was found to be essential for trafficking, both of α,δ itself, and for its effect on the α subunits (Canti et al., 2005; Cassidy et al., 2014; Hoppa et al., 2012).

The skeletal muscle calcium channel complex also contains a γ subunit, now called γ1 (Takahashi et al., 1987) (Figure 2(b)), but γ is not associated with other calcium channels, and further members of this ‘γ subunit’ family are now known to be trafficking proteins that modulate the function of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptors, rather than voltage-gated calcium channel subunits (Tomita et al., 2003). The roles of the different calcium channel auxiliary proteins being lower voltage-activated than α,δ (Koschak et al., 2001; Xu and Lipscombe, 2001). Finally, a fourth L-type channel was identified because of its role in a genetic form of night blindness (Bech et al., 1998; Strom et al., 1998), and this was also shown to have properties distinguishing it from the other L-type channels (Koschak et al., 2003).

Following the cloning and initial study of all the calcium channel α subunits identified in the mammalian genome, a rationalised nomenclature was adopted in 2000, grouping the α1 subunits into CaV1 (L-type), CaV2 (non-L-type) and CaV3 (T-type) (Ertel et al., 2000) (Table 1). Since that time the distinct properties of multiple splice variants of these channels have also been recognised.
Elucidation of physiological channel function from knockout mouse studies and genetic mutations

Several spontaneously arising mouse loss-of-function mutants were identified which gave important clues as to the function of the channel subunits. This was particularly true for CaV2.1, β4 and α2δ-2 which are strongly expressed in cerebellum, and whose mutation produced obvious ataxias (Barclay et al., 2001; Burgess et al., 1997; Fletcher et al., 1996). Subsequent targeted knockouts gave similar phenotypes. A surprise came with the knockout of NaAb, a single domain channel gated channel was obtained using a mutant form of a bacterial sodium channel homolog, NaAb, a single domain channel which forms homo-tetramers (Payandeh et al., 2011). This was mutated so that the pore became Ca2+-selective, forming CaVAb. This structure has provided multiple insights, including confirmation of the Ca2+ permeation process (Tang et al., 2014). Remarkably, this channel was sensitive to calcium channel antagonists, yielding further important insight into the binding and mechanism of action of these drugs (Tang et al., 2016). For mammalian calcium channel complexes, although low-resolution single particle electron microscopic structures were published previously (Serysheva et al., 2002; Walsh et al., 2009; Wolf et al., 2003), major advances in cryo-electron microscopy were needed before a detailed structure of the skeletal muscle calcium channel was produced, very beautifully elucidating details of the pore and the subunit arrangement (Wu et al., 2016). GPI-anchoring of α1 subunit with the VWA and Cache domains (which have similarity to bacterial chemotaxis domains) of α1 subunit (Canti et al., 2005; Cassidy et al., 2009), and interaction of the α1 subunit with the G-protein (Gutman et al., 2010, 2014), were confirmed in the structure (Wu et al., 2016).

Calcium channel modulation

Only two canonical second messenger modulation pathways will be considered here, for reasons of space: inhibitory modulation of neuronal calcium channels by G-proteins, and cyclic AMP-dependent phosphorylation, mediating enhancement of L-type channels. Many other pathways also deserve mention, including Ca2+-calmodulin control of Ca2+-dependent inactivation and facilitation of L-type and P-type channels, studied extensively by the late David Yue (Dick et al., 2008; Peterson et al., 1999).

Structural studies

The first components of the calcium channel complex to be amenable to structural studies were the β subunits, which contain two conserved interacting domains (SH3 and guanylate kinase-like), the latter binding to the linker between domains I and II of the channels (Chen et al., 2004; Opalowsky et al., 2004; Pragnell et al., 1994; Richards et al., 2004; Van Petegem et al., 2004).

The first crystal structure for a calcium-selective voltage-gated channel was obtained using a mutant form of a bacterial sodium channel homolog, NaAb, a single domain channel which forms homo-tetramers (Payandeh et al., 2011). This was mutated so that the pore became Ca2+-selective, forming CaVAb. This structure has provided multiple insights, including

<table>
<thead>
<tr>
<th>Activation voltage</th>
<th>Functional nomenclature</th>
<th>Channel α1 subunit</th>
<th>CaV nomenclature</th>
<th>Main function</th>
</tr>
</thead>
<tbody>
<tr>
<td>(High)</td>
<td>L</td>
<td>α5</td>
<td>1.1</td>
<td>Skeletal muscle voltage sensor</td>
</tr>
<tr>
<td>High</td>
<td>L</td>
<td>α3</td>
<td>1.2</td>
<td>Cardiac, smooth muscle function</td>
</tr>
<tr>
<td>Medium</td>
<td>L</td>
<td>α2</td>
<td>1.3</td>
<td>Hearing, sino-atrial node function</td>
</tr>
<tr>
<td>Medium</td>
<td>L</td>
<td>α1</td>
<td>1.4</td>
<td>Retinal neurotransmission</td>
</tr>
<tr>
<td>High</td>
<td>PQ</td>
<td>α2</td>
<td>2.1</td>
<td>Synaptic transmission in CNS, motor nerves and elsewhere</td>
</tr>
<tr>
<td>High</td>
<td>N</td>
<td>α2</td>
<td>2.2</td>
<td>Synaptic transmission in PNS (and CNS, especially early in development)</td>
</tr>
<tr>
<td>Medium</td>
<td>R</td>
<td>α1</td>
<td>2.3</td>
<td>Present in some neurons and synapses</td>
</tr>
<tr>
<td>Low</td>
<td>T</td>
<td>α2</td>
<td>3.1</td>
<td>Neuronal excitability, pacemaker activity, subthreshold oscillations</td>
</tr>
<tr>
<td>Low</td>
<td>T</td>
<td>α2</td>
<td>3.2</td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>T</td>
<td>α2</td>
<td>3.3</td>
<td></td>
</tr>
</tbody>
</table>

PNS: peripheral nervous system; CNS: central nervous system.

G-protein modulation

Voltage-dependent activation of neuronal calcium channels is required for neurotransmitter release, and this process can be inhibited by a range of modulatory neurotransmitters coupled to seven-transmembrane receptors (Dolphin, 1982; Jessell and Iversen, 1977; Peng and Frank, 1989), leading to the view that inhibitory modulation of the calcium channel-mediated component of the presynaptic action potential underpins receptor-mediated presynaptic inhibition (Dolphin et al., 1986; Dunlap and Fischbach, 1978; Ikeda and Schofield, 1989) (Figure 3(a)). Modulation of neurotransmitter release was found to be mediated by a pertussis toxin-sensitive GTP-binding protein, of the G1/G0 family (Dolphin and Prestwich, 1985). The inhibitory
modulation of neuronal calcium currents was subsequently also identified to involve these G-proteins (Scott and Dolphin, 1986; Holz et al., 1986) (Figure 3(c)). Using both native and cloned CaV2.2 channels, the modulation was subsequently shown to be a direct membrane-delimited effect of Gβγ subunits (Herlitze et al., 1996; Ikeda, 1996), mediated by the channel I-II linker (Bourinet et al., 1996) and its intracellular N-terminus (Page et al., 1996). The characteristic voltage-dependence of the inhibition, which means that inhibition is lost with large or repeated depolarisations, was shown to require participation of the calcium channel β subunit (Meir et al., 2000).

Cyclic AMP-dependent phosphorylation

Another key example of second messenger modulation is provided by L-type calcium channels, which are potentiated by β-adrenergic receptor activation, via a cyclic AMP-dependent mechanism (Cachelin et al., 1983; Reuter, 1983). In heart, this effect is mediated by β1-adrenergic receptors and forms one of the main components of the fight-or-flight response. However, it has been difficult to reproduce when cloned CaV1.2 calcium channels are expressed, for example, in HEK-293 cells, suggesting it is more complex than simple channel phosphorylation, and indeed, the role of the several protein kinase A substrate serines in cardiac CaV1.2 function is still being determined (Lemke et al., 2008; Yang et al., 2016). Furthermore, the response to β-adrenergic stimulation may involve a proteolytically cleaved C-terminal fragment of the endogenous CaV1.2 channels (Fu et al., 2013; Fuller et al., 2010). Perhaps surprisingly, there appears to be a somewhat different basis for the spatially restricted stimulation observed in hippocampal neurons following activation by β2-adrenergic receptors of neuronal CaV1.2 channels (Qian et al., 2017).

Future research

The selective pharmacology that has been so important for dissecting out the functions of different calcium channels is still incomplete. Although a selective inhibitor of the T-type calcium channels exists (Dreyfus et al., 2010), it does not differentiate between the CaV3.3 channels. Similarly, there are currently no selective inhibitors of the different CaV1 channels. Such inhibitors that would be able to differentiate between these very similar channels could have important therapeutic possibilities. For example, selective inhibition of CaV3.2 could be of therapeutic benefit in certain types of pain (Margat et al., 2011), and selective inhibitors of CaV1.3 have potential for therapeutic use in Parkinson’s disease and other disorders (Striessnig et al., 2015). Furthermore, although ω-conotoxin GVIA is a selective blocker of N-type channels and a related compound is licenced for use intrathecally in some chronic pain conditions (Miljanich, 2004), no small molecule inhibitors of N-type channels have yet been shown to be effective in clinical trials for chronic pain.

Future challenges include a full understanding of how particular calcium channels are trafficked into precise subcellular domains, for example, how some channels are targeted to dendrites (Hall et al., 2013), while others are directed to presynaptic active zones to mediate neurotransmitter release (Kaeser et al., 2011). Furthermore, calcium channels have been found to interact, directly or indirectly, with multiple scaffolding proteins, ion channels and second messenger pathways (Müller et al., 2010), but how these are organised and function together remains to be elucidated. Related to this, the pathways for intracellular Ca2+ signalling to the nucleus and the selectivity for L-type Ca2+ channels in neurons are still being revealed (Cohen et al., 2015; Wheeler et al., 2012).

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding

This work was supported by a Wellcome Trust Investigator award (098360/Z/12/Z) and a Royal Society Leverhulme Senior Fellowship to A.C.D.

References


Hamill OP, Marty A, Neher E, et al. (1981) Improved patch-clamp techniques for high resolution current recording from cells and cell-free


